In a blinded , randomized , three-arm placebo-controlled clinical trial , 80 participants with diabetic nephropathy taking lisinopril ( 80 mg ) were randomized to spironolactone ( 25 mg daily ) , losartan ( 100 mg daily ) , or placebo ( trial dates from July of 2003 to December of 2006 ) .